Advances in imaging Parkinson's disease

Current Opinion in Neurology

Volumn 10, Issue 4, 1997, Pages 327-331

  Brooks, David J ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; FLUORODEOXYGLUCOSE F 18;

CAUDATE NUCLEUS; DISEASE COURSE; DOPAMINERGIC SYSTEM; GLUCOSE METABOLISM; HUMAN; IMAGE ANALYSIS; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; PUTAMEN; RELATIVE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATE CORTEX;

EID: 0030748848     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199708000-00008     Document Type: Review

References (67)

1. Duguid JR, De La Paz R, DeGroot J: Magnetic resonance imaging of the midbrain in Parkinson's disease. Ann Neurol 1986, 20:744-747.
2. Rutledge JN, Hilal SK, Silver AJ, Defendini R, Fahn S: Study of movement disorders and brain iron by MR. Am J Radiol 1987, 149:365-379.
3. 2 relaxation-time in patients with Parkinson's disease. Neurology 1993, 43:697-700.
4. Savoiardo M, Girotti F, Strada L, Ciceri E: Magnetic resonance imaging in progressive supranuclear palsy and other parkinsonian disorders. J Neural Transm 1994, (suppl 42):93-110.
5. Gorell JM, Ordridge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA: Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 1995, 45:1138-1143.
6. Drayer BP, Olanow W, Burger P, Johnson GA, Herfkens R, Riederer S: Parkinson Plus syndrome: diagnosis using high field MR imaging of brain iron. Radiol 1986, 159:493-498.
7. Konayaga M, Konayaga Y, Iida M: Clinical and magnetic resonance imaging study of extrapyramidal symptoms in multiple system atrophy. J Neurol Neurosurg Psychiatry 1994, 57:1528-1531.
8. Yagishita Y, Oda M: Progressive supranuclear palsy - MRI and pathological findings. Neuroradiology 1996, 38(suppl 1):S60-S66.
9. Friston KJ, Frith CD, Liddle PF, Dolan RJ, Lammertsma AA, Frackowiak RSJ: The relationship between global and local changes in PET scans. J Cereb Blood Flow Metab 1990, 10:458-466.
10. Firnau G, Sood S, Chirakal R, Nahmias C, Garnett ES: Cerebral Metabolism of 6-[18F]Fluoro-L-3,4-Dihydroxyphenylalanine in the primate. J Neurochem 1987, 48:1077-1082.
11. Garnett ES, Nahmias C, Firnau G: Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography. Can J Neurol Sci 1984, 11:174-179.
12. Nahmias C, Garnett ES, Firnau G, Lang A: Striatal dopamine distribution in Parkinsonian patients during life. J Neurol Sci 1985, 69:223-230.
13. Leenders KL, Palmer A, Turton D, Quinn N, Firnau G, Garnett S, Nahmias C, Jones T, Marsden CD: DOPA uptake and dopamine receptor binding visualized in the human brain in vivo. In Recent Developments in Parkinson's Disease. Edited by Fahn S, Marsden CD, Jenner P, Teychenne P. New York; Raven Press; 1986:103-113.
14. 18F-dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1990, 28:547-555.
15. Leenders KL, Palmer AJ, Quinn N, Clark JC, Firnau G, Garnett ES, Nahmias C, Jones T, Marsden CD: Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 1986, 49:853-860.
16. Martin WRW, Stoessl AJ, Adam MJ, Ammann W, Bergstrom M, Harrop R, Lainehan R, Rogers GG, Ruth TJ, Sayre CI et al.: Positron emission tomography in Parkinson's disease: glucose and dopa metabolism. Adv Neurol 1986, 45:95-98.
17. 18]dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 1995, 59:597-600.
18. 18F-dopa PET in early and advanced Parkinson's disease [Abstract]. Movement Disord 1996, 11 (suppl 1):147.
19. 18F] Fluorodopa studies. In Quantification of Brain Function Using PET. Edited by Myers R, Cunningham V, Bailey D, Jones T. San Diego: Academic Press; 1996:82-87.
20. Roberts AC, Desalvia MA, Wilkinson LS, Collins P, Muir JL, Everitt BJ, Robbins TW: 6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin card sort test - possible interactions with subcortical dopamine. J Neurosci 1994, 14:2531-2544.
21. Tedroff J, Aquilonius S-M, Laihinen A, Rinne U, Hartvig P, Andersson J, Lundqvist H, Haarparanta M, Solin O, Antoni G et al.: Striatal kinetics of [11C]-( + )-nomifensine and 6-[18F]fluoro-L-dopa in Parkinson's disease measured with positron emission tomography. Acta Neurol Scand 1990, 81:24-30.
22. Tedroff J, Aquilonius S-M, Hartvig P, Lundqvist H, Gee AG, Uhlin J, Långström B: Monoamine re-uptake sites in the human brain evaluated in vivo by means of 11C-nomifensine and positron emission tomography: the effects of age and Parkinson's disease. Acta Neurol Scand 1988, 77:192-201.
23. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993, 34:423-431.
24. 123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995, 38:589-598.
25. 123I]β-CIT for SPECT imaging of dopamine transporters in Parkinson's disease [Abstract]. Movement Disord 1996, 11 (suppl 1):110.
26. 123I-IPT and SPECT in patients with Parkinson's disease and controls [Abstract]. Movement Disord 1996, 11 (suppl 1):104.
27. 11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease [Abstract]. Neurology 1996, 46 (suppl):A454.
28. Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F, Neumeyer J, Margouleff C, Babchyk B, Zanzi I, Eidelberg D: Comparative nigrostriatal dopaminergic imaging with iodine-123 beta-CIT-FP/SPECT and fluorine-18 FDOPA/PET. J Nucl Med 1996, 37:1760-1765.
29. Koeppe RA, Frey KA, Vander Borght TM, Kilbourn MR, Jewett DM, Lee LC, Kuhl DE: Kinetic evaluation of [C-11]dihydrotetrabenazine (DTBZ) by dynamic PET: A marker for the vesicular dopamine transporter [Abstract]. J Cereb Blood Flow Metabol 1995, 15 (suppl 1):S651.
30. Tatsch K, Schwarz J, Mozley PD, Linke R, Pogarell O, Oertel WH, Fieber RS, Hahn K, Kung HF: Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [I-123]IPT and SPECT. Eur J Nucl Med (in press).
31. Salmon EP, Brooks DJ, Leenders KL, Turton DR, Hume SP, Cremer JE, Jones T, Frackowiak RSJ: A two-compartment description and kinetic procedure for measuring regional cerebral [11C]nomifensine uptake using positron emission tomography. J Cereb Blood Flow Metab 1990, 10:307-316.
32. Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sagar H, Jones T, Marsden CD, Frackowiak RSJ: The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990, 47:1290-1298.
33. Brucke T, Asenbaum S, Pirker W, Pozzera A, Wenger S, Wober Ch, Muller Ch, Angelberger P, Podreka I: Quantification of dopaminergic nerve cell loss in Parkinson's disease with [I-123]-β-CIT [Abstract]. J Cereb Blood Flow Metab 1995, 15 (suppl 1):S37.
34. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997, 62:133-140.
35. Marek K, Seibyl JP, Zoghbi SS, Zeaponce Y, Baldwin RM, Fussell B, Charney DS, Vandyck C, Hoffer PB, Innis RB: [I-123] beta-CIT SPECT imaging demonstrates bilateral loss of dopamine transporters In hemiparkinsons disease. Neurology 1996, 46:231-237.
36. Golbe LI: The genetics of Parkinson's disease: a reconsideration. Neurology 1990, 40 (suppl 3):7-16.
37. 18F-dopa PET study. Ann Neurol 1997, 41:222-229. This report demonstrates a 30% prevalence of preclinical nigral dysfunction in at-risk asymptomatic adult relatives of patients with familial PD.
38. 18F-dopa PET. Adv Neurol 1997, (in press).
39. 18F-dopa and positron emission tomography. Neurology 1992, 42:1894-1900.
40. Holthoff VA, Vieregge P, Kessler J, Pietrzyk U, Herholz K, Bonner J, Wagner R, Wienhard K, Pawlik G, Heiss WD: Discordant twins with Parkinson's disease - positron emission tomography and early signs of impaired cognitive circuits. Ann Neurol 1994, 36:176-182.
41. Vingerhoets FJG, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB: Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 1994, 36:759-764.
42. 18F]dopa PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996, 119:585-591. This is the first in-vivo functional imaging study to demonstrate that early PD is actively progressive with a short preclinical window.
43. 18F]-6-L-Fluorodopa studies in two patients with putaminal implants. Ann Neurol 1992, 31:166-173.
44. Lindvall O, Sawle G, Widner H, Rothwell JC, Bjorklund A, Brooks D, Brundin P, Frackowiak R, Marsden CD, Odin P et al.: Evidence for long term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 1994, 35:172-180.
45. Widner H, Tetrud J, Rehncrona S, Snow B, Brundin P, Gustavii B, Bjorklund A, Lindvall O, Langston JW: Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med 1992, 327:1556-1563.
46. Freeman TB, Olanow CW, Hauser RA, Nauert GM, Smith DA, Borlongan CV, Sanberg PR, Holt DA, Kordower JH, Vingerhoets FJG et al.: Bilateral fetal nigral transplantion into the post-commisural putamen as a treatment for Parkinson's disease: six months follow-up. Ann Neurol 1995, 38:379-388.
47. 18F]fluorodopa uptake in five grafted parkinsonian patients. Ann Neurol 1995, 38:580-588.
48. Wenning GK, Odin P, Morrish PK et al.: Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disase. Ann Neurol (in press).
49. Kordower JH, Freeman TB, Snow BJ, Vingerhoets FJG, Mufson EJ, Sanberg PR, Hauser RA, Smith DA, Nauert GM, Perl DP et al.: Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995, 332:1118-1124.
50. Miletich RS, Chan T, Gillespie M, Di Chiro G, Stein S: Contralateral basal ganglia metabolism is abnormal in hemiparkinsonian patients. An FDG-PET study [Abstract]. Neurology 1988, 38:S260.
51. Wolfson LI, Leenders KL, Brown LL, Jones T: Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson's disease. Neurology 1985, 35:1399-1405.
52. Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, Chaly T, Robeson T, Margouleff D, Przedborski S et al.: The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994, 14:783-801.
53. Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Chaly T, Belakhlef A, Mandel F, Przedborski S, Fahn S: Early differential diagnosis of Parkinson's disease with F-18 fluorodeoxyglucose and positron emission tomography. Neurology 1995, 45:1995-2004.
54. Perlmutter JS, Raichle ME: Regional blood flow in hemiparkinsonism. Neurology 1985, 35:1127-1134.
55. Kuhl DE, Metter EJ, Riege WH, Markham CH: Patterns of cerebral glucose utilisation in Parkinson's disease and Huntington's disease. Ann Neurol 1984, 15 (suppl):S119-S125.
56. Peppard RF, Martin WRW, Guttman M, McGeer PL, Walsh EM, Carr GD, Phillips AG, Grochowski E, Okada J, Tsui JKC et al.: The relationship of cerebral glucose metabolism to cognitive deficits in Parkinson's disease [Abstract]. Neurology 1988, 38 (suppl 1):364.
57. Kuhl DE, Metter EJ, Benson DF, Ashford JW, Riege WH, Fujikawa DG, Markham CH, Mazziotta JC, Maltese A, Dorsey DA: Similarities of cerebral glucose metabolism in Alzheimer's and Parkinsonian dementia. J Cereb Blood Flow Metab 1985, 5:S169-S170.
58. Kuhl DE, Metter EJ, Riege WH: Patterns of local cerebral glucose utilisation determined in Parkinson's disease by the 18F-fluorodeoxyglucose method. Ann Neurol 1984, 15:419-424.
59. 1BF-dopa uptake: difference in Parkinson's disease and atypical parkinsonism. J Neurol Neurosurg Psychiatry 1991, 54:898-904.
60. De Volder AG, Francard J, Laterre C, Dooms G, Bol A, Michel C, Goffinet AM: Decreased glucose utilisation in the striatum and frontal lobe in probable striatonigral degeneration. Ann Neurol 1989, 26:239-247.
61. Eidelberg D, Takikawa S, Moeller JR, Dhawan V, Redington K, Chaly T, Robeson W, Dahl JR, Margouleff D, Fazzini E et al.: Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. Ann Neurol 1993, 33:518-527.
62. Davie CA, Wenning GK, Barker GJ, Tofts PS, Phil D, Kendall BE, Quinn N, McDonald Wl, Marsden CD, Miller DH: Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann Neurol 1995, 37:204-210.
63. Brooks DJ, Salmon EP, Mathias CJ, Quinn N, Leenders KL, Bannister R, Marsden CD, Frackowiak RSJ: The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system, in patients with multiple system atrophy, pure autonomie failure, and Parkinson's disease, studied with PET. Brain 1990, 113:1539-1552.
64. 18F-dopa PET data. J Neurol Neurosurg Psychiatry 1994, 57:278-284.
65. 11C-raclopride and PET. Ann Neurol 1992, 31:184-192.
66. 2 receptor s in Parkinson's disease and striato-nigral degeneration determined by positron emission tomography. In Basic, Clinical, and Therapeutic Advances of Alzheimer's and Parkinson's Diseases, vol 2. Edited by Nagatsu T. New York: Plenum Press; 1990:107-110.
67. 123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de-novo parkinsonism. Neurology 1992, 42:556-561.